The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study
- 28 February 2005
- journal article
- research article
- Published by Elsevier BV in Bone
- Vol. 36 (2), 358-364
- https://doi.org/10.1016/j.bone.2004.10.014
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly WomenJournal of Bone and Mineral Research, 2004
- Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture RiskJournal of Bone and Mineral Research, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJama-Journal Of The American Medical Association, 2002
- Upper Gastrointestinal Tract Safety of Risedronate: A Pooled Analysis of 9 Clinical TrialsMayo Clinic Proceedings, 2002
- Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene TherapyJournal of Bone and Mineral Research, 2002
- A method to assess the proportion of treatment effect explained by a surrogate endpointStatistics in Medicine, 2001
- The Efficacy and Tolerability of Alendronate in Postmenopausal Osteoporotic Chinese Women: A Randomized Placebo-Controlled StudyCalcified Tissue International, 2000
- Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled TrialJournal of Clinical Endocrinology & Metabolism, 2000
- Normal ranges for vertebral height ratios and prevalence of vertebral fracture in hong kong chinese: A comparison with American caucasiansJournal of Bone and Mineral Research, 1996
- Hip fractures in the elderly: A world-wide projectionOsteoporosis International, 1992